...
ktta-img

Pasithea Therapeutics Corp, Common Stock

KTTA

NAQ

$3.03

-$0.02

(-0.66%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$3.60M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
5.88K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.82
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.8 L
$9.6 H
$3.03

About Pasithea Therapeutics Corp, Common Stock

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameKTTASectorS&P500
1-Week Return2.69%-1.66%0.16%
1-Month Return-7.58%-3.08%1%
3-Month Return-28.24%-6.66%10.69%
6-Month Return-45.54%-1.54%12.9%
1-Year Return-65.5%8.85%30.94%
3-Year Return-94.09%7.9%29.66%
5-Year Return-95.72%45.12%92.82%

Financials

Dec '20Dec '21Dec '22Dec '23
Total Revenue-15.06K486.56K486.56K[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":3.1,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue-17.27K113.19K648.45K[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":2.66,"profit":true},{"date":"2022-12-31","value":17.46,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit-(2.21K)373.36K(648.45K)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-0.59,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-173.68,"profit":false}]
Gross Margin-(14.69%)76.74%(133.27%)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-19.15,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-173.68,"profit":false}]
Operating Expenses40.98K4.51M15.19M15.98M[{"date":"2020-12-31","value":0.26,"profit":true},{"date":"2021-12-31","value":28.19,"profit":true},{"date":"2022-12-31","value":95.06,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(40.98K)(4.51M)(14.82M)(15.98M)[{"date":"2020-12-31","value":-4098000,"profit":false},{"date":"2021-12-31","value":-450741300,"profit":false},{"date":"2022-12-31","value":-1481632100,"profit":false},{"date":"2023-12-31","value":-1597936100,"profit":false}]
Total Non-Operating Income/Expense-2.33M860.98K714.05K[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":36.9,"profit":true},{"date":"2023-12-31","value":30.6,"profit":true}]
Pre-Tax Income(40.98K)(2.17M)(13.94M)(15.51M)[{"date":"2020-12-31","value":-4098400,"profit":false},{"date":"2021-12-31","value":-217352100,"profit":false},{"date":"2022-12-31","value":-1393645200,"profit":false},{"date":"2023-12-31","value":-1550774800,"profit":false}]
Income Taxes(61.48K)508.00(879.97K)453.91M[{"date":"2020-12-31","value":-0.01,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-0.19,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes-(2.17M)(13.06M)(469.42M)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-217402900,"profit":false},{"date":"2022-12-31","value":-1305648100,"profit":false},{"date":"2023-12-31","value":-46941774800,"profit":false}]
Income From Continuous Operations-(2.17M)(13.94M)(16.74M)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-217352100,"profit":false},{"date":"2022-12-31","value":-1393645200,"profit":false},{"date":"2023-12-31","value":-1673845500,"profit":false}]
Income From Discontinued Operations----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(40.98K)(2.17M)(13.06M)(15.96M)[{"date":"2020-12-31","value":-4098400,"profit":false},{"date":"2021-12-31","value":-217402900,"profit":false},{"date":"2022-12-31","value":-1305648100,"profit":false},{"date":"2023-12-31","value":-1596165800,"profit":false}]
EPS (Diluted)(0.07)(0.14)(0.53)(5.30)[{"date":"2020-12-31","value":-7.1,"profit":false},{"date":"2021-12-31","value":-13.81,"profit":false},{"date":"2022-12-31","value":-53,"profit":false},{"date":"2023-12-31","value":-530.42,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

KTTA
Cash Ratio 14.18
Current Ratio 14.81

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

KTTA
ROA (LTM) -37.90%
ROE (LTM) -63.25%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

KTTA
Debt Ratio Lower is generally better. Negative is bad. 44.21
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.96

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

KTTA
Trailing PE NM
Forward PE NM
P/S (TTM) 42.15
P/B 0.20
Price/FCF NM
EV/R 277.44
EV/Ebitda 2.90

FAQs

What is Pasithea Therapeutics Corp share price today?

Pasithea Therapeutics Corp (KTTA) share price today is $3.03

Can Indians buy Pasithea Therapeutics Corp shares?

Yes, Indians can buy shares of Pasithea Therapeutics Corp (KTTA) on Vested. To buy Pasithea Therapeutics Corp from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in KTTA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Pasithea Therapeutics Corp be purchased?

Yes, you can purchase fractional shares of Pasithea Therapeutics Corp (KTTA) via the Vested app. You can start investing in Pasithea Therapeutics Corp (KTTA) with a minimum investment of $1.

How to invest in Pasithea Therapeutics Corp shares from India?

You can invest in shares of Pasithea Therapeutics Corp (KTTA) via Vested in three simple steps:

  • Click on Sign Up or Invest in KTTA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Pasithea Therapeutics Corp shares
What is Pasithea Therapeutics Corp 52-week high and low stock price?

The 52-week high price of Pasithea Therapeutics Corp (KTTA) is $9.6. The 52-week low price of Pasithea Therapeutics Corp (KTTA) is $2.8.

What is Pasithea Therapeutics Corp price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Pasithea Therapeutics Corp (KTTA) is

What is Pasithea Therapeutics Corp price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Pasithea Therapeutics Corp (KTTA) is 0.20

What is Pasithea Therapeutics Corp dividend yield?

The dividend yield of Pasithea Therapeutics Corp (KTTA) is 0.00%

What is the Market Cap of Pasithea Therapeutics Corp?

The market capitalization of Pasithea Therapeutics Corp (KTTA) is $3.60M

What is Pasithea Therapeutics Corp’s stock symbol?

The stock symbol (or ticker) of Pasithea Therapeutics Corp is KTTA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top